1202 related articles for article (PubMed ID: 30981696)
21. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Guan H; Sheng Y; Guo W; Han S; Shi L
Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
24. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
25. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
29. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
31. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
[TBL] [Abstract][Full Text] [Related]
33. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
Masuda N; Ohe Y; Gemma A; Kusumoto M; Yamada I; Ishii T; Yamamoto N
Cancer Sci; 2019 Apr; 110(4):1401-1407. PubMed ID: 30776174
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
[TBL] [Abstract][Full Text] [Related]
36. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S
J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132
[TBL] [Abstract][Full Text] [Related]
37. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
Li H; Lai L; Wu B
Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
[TBL] [Abstract][Full Text] [Related]
38. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J; Helland Å; Oh IJ; Migliorino MR; Dziadziuszko R; Wrona A; de Castro J; Mazieres J; Griesinger F; Chlistalla M; Cardona A; Ruf T; Trunzer K; Smoljanovic V; Novello S
ESMO Open; 2022 Feb; 7(1):100333. PubMed ID: 35042152
[TBL] [Abstract][Full Text] [Related]
39. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
